Biopharma | February 24, 2026
ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Subscribe To Our Newsletter & Stay Updated
